Markets Wired

Stock Insights on Depomed, Inc. (NASDAQ:DEPO)

April 08
09:22 2015

Depomed, Inc. (NASDAQ:DEPO) (TREND ANALYSIS) shares were traded with no significant volume change. The stock closed last trading session at $23.16, up by 1.58%, with a volume of 1,363,817 shares against an average volume for the last 30 days of 1,807,502.

Depomed, Inc. (DEPO) reported last quarter earnings figures on February 23rd. The company announced actual earnings per share of $1.23 against the consensus Street estimate of $0.08. This represents a year-on-year increase of earning per share of $0.51 from corresponding quarter of last year. Depomed, Inc. posted revenue of $194.6 million.

Stock Performance: Click here for a free comprehensive Trend Analysis Report

The company is currently valued at $1.38 billion and closed the last trading session at $23.16. The stock has 50-day moving average of $21.54 and a 200-day moving average of $16.33.

Depomed, Inc. (NASDAQ:DEPO) is currently trading 9.32% below its 52-week-high, 135.13% above its 52-week-low and in the range of $21.21-$25.54 over the past month. The 1-year range for the stock is $9.85-$25.54. Depomed, Inc. (DEPO) has a price to book ratio of 3.77 versus Nasdaq average of 4.63. The company’s share price has outperformed the Nasdaq year to date by over 42.55%.

Depomed, Inc. (DEPO) current short interest stands at 10,130,479 shares. It has increased by 34% from the same period of last month. Around 17.1% of the company’s shares, which are float, are short sold. With a 30-days average daily volume of 1,807,502 shares, the number of days required to cover the short positions stand at 4.9 days.

Stock Analyst Perspectives: Click here for a free Trend Analysis Report

There are currently six analysts that we track that cover DEPO. Of those six, four have a buy rating, two have a hold rating. On a consensus basis this yields to a Buy. The overall consensus target price stands at $27.63 which represents an upside of 19.28% from the last closing price of $23.16.

Recently, several research firms updated their ratings on the stock. Indeed, in the last five days, an average price target of $28.33 has been given to the stock, which represents an upside of 22.34% from the last closing price.

Indeed, Wallachbeth Capital LLC maintained their hold stance on April 07th, with a target price of $26, which represents an upside of 12.26% from the last closing price. Another research firm, RBC Capital Markets, reiterated their outperform stance on April 06th, with a target price of $29, which translates into an upside of 25.22%.

Company Profile

DepoMed, Inc. develops new and proprietary oral drug delivery technologies. The Company has developed a system designed to be retained in the stomach for an extended period of time while it delivers the incorporated drug or drugs. DepoMed has also developed a system designed to reduce gastrointestinal irritation.


About Author

Lauren Miller

Lauren Miller

Lauren Miller covers Business and Telecom Services for Markets Wired. Lauren joined Evergreen in 2013 after serving as an associate in equity research at Donaldson, Lufkin & Jenrette for 5 years.

Related Articles